Use the boxes below to ask us a question, or to see if you have a case that we may be able to help you with:

Cymbalta may worsen liver disease

FDA warns anti-depressant drug Cymbalta may worsen liver disease in patients with underlying conditions - 10/17/05

The anti-depressant drug Cymbalta should not be prescribed for patients with liver disease or any liver insufficiency because the drug might worsen their underlying conditions, the FDA stated today. Cymbalta was approved in August 2004 to treat major depressive disorder as well as nerve pain associated with diabetes, and more than 1 million people are estimated to be taking it. However, several reports of liver injury in patients who are taking the drug have led the FDA to issue a consumer warning.

Cymbalta's label already warns patients of the possibility of liver injury, and doctors were cautioned not to prescribe Cymbalta to patients with alcohol addiction because clinical studies showed that some patients experienced liver damage when they consumed Cymbalta with alcohol. Lilly issued a letter to healthcare professionals October 5, 2005, with the updated warning information. Lilly has also received reports of patients with jaundice while on Cymbalta.

Source: Jennifer Corbett Dooren, "FDA, Eli Lilly warn on liver damage with Cymbalta," Miami Herald, October 17, 2005.

The Latest News in Drugs Linked to Personal Injury:

June. 2007
Wed. 06 :	Accutane patient awarded $2.5 million in damages
Tue. 05 :	Ohio mother files wrongful death lawsuit against Bayer
Mon. 04 :	Canadian consumers sue Merck over Fosamax drug

May. 2007
Fri. 25 :	WV deputy marshal latest to bring lawsuit against Zicam maker
Fri. 25 :	Amgen’s Vectibix not approved by European Medicines Agency
Wed. 23 :	Novartis’ Exjade could cause kidney failure, death
Mon. 21 :	TX woman with kidney damage files lawsuit against Fleet
Fri. 11 :	FDA Committee Advises Limiting Epogen, Procrit and Aranesp
Tue. 08 :	Toddlers Whose Mothers Took Depakote Suffer Mental Retardation
Thu. 03 :	FDA Names 24 Websites Linked to Counterfeit Drugs
Thu. 03 :	Changes to Black Box Warnings for AntiDepressants Proposed

December. 2006
Tue. 05 :	Antidepressant use increases suicide attempts
Mon. 04 :	Pfizer’s torcetrapib canceled after deaths
Fri. 01 :	Cubist seeks expansion of Cubicin
Fri. 01 :	Ketek investigation forces standoff between FDA and Grassley

November. 2006
Wed. 29 :	Statin drug use no benefit
Mon. 27 :	Pfizer: use Celebrex for childhood arthritis
Fri. 24 :	Seroquel maker warned by FDA for misleading material
Tue. 21 :	Cephalon under investigation for Actiq marketing
Mon. 20 :	FDA issues health advisory over Procrit
Thu. 16 :	FDA convenes Ketek safety panel
Mon. 13 :	Tamiflu patients warned of abnormal behavior
Thu. 02 :	Paxil suit settles for $63.8 million
Wed. 01 :	Blood-pressure increase concern for Pfizer drug
Wed. 01 :	Plavix personal injury lawsuit filed